binx io CT/NG Test

About Binx Health

Binx Health is a commercial-stage diagnostics company specializing in decentralized, point-of-care molecular testing. Its core offering is the binx io, an FDA-cleared, CLIA-waived platform that delivers results for chlamydia and gonorrhea in approximately 30 minutes, enabling single-visit 'test and treat' models. The company is actively expanding its commercial footprint through national distribution agreements and strategic partnerships aimed at increasing access in clinics, colleges, and public health programs. Following the 2023 sale of its consumer testing business to imaware, Binx Health appears focused on scaling its point-of-care platform and related professional services.

Therapeutic Areas